Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Total Non-Current Liabilities (2016 - 2025)

Dare Bioscience's Total Non-Current Liabilities history spans 11 years, with the latest figure at $24.2 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 3.76% year-over-year to $24.2 million; the TTM value through Dec 2025 reached $24.2 million, up 3.76%, while the annual FY2025 figure was $24.2 million, 3.76% up from the prior year.
  • Total Non-Current Liabilities reached $24.2 million in Q4 2025 per DARE's latest filing, up from $22.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $32.7 million in Q4 2022 to a low of $6.1 million in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $20.4 million, with a median of $21.6 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 96.9% in 2021, then plummeted 31.48% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $17.1 million in 2021, then skyrocketed by 91.84% to $32.7 million in 2022, then tumbled by 31.48% to $22.4 million in 2023, then increased by 4.24% to $23.4 million in 2024, then grew by 3.76% to $24.2 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's Total Non-Current Liabilities are $24.2 million (Q4 2025), $22.7 million (Q3 2025), and $20.8 million (Q2 2025).